Publication:
A randomized double-blind controlled trial of Lactobacillus acidophilus plus bifidobacterium bifidum versus placebo in patients with hypercholesterolemia

dc.contributor.authorRerksuppaphol S.
dc.contributor.authorRerksuppaphol L.
dc.date.accessioned2021-04-05T03:25:54Z
dc.date.available2021-04-05T03:25:54Z
dc.date.issued2015
dc.date.issuedBE2558
dc.description.abstractBackground: Hypercholesterolemia is a major risk factor for cardiovascular disease. Not all patients respond well to traditional cholesterol lowering medications. Probiotics have been evaluated for their cholesterol-lowering effects in humans with variable results. This study was performed to evaluate the efficacy of two probiotics in lowering the serum cholesterol of hypercholesterolemic patients. Materials and Methods: A randomized double-blind controlled trial was conducted comparing placebo to Lactobacillus acidophilus plus Bifidobacterium bifidum in patients diagnosed with hypercholesterolemia. Placebo or probiotic capsules were taken three times daily for six weeks. Pre- and post-treatment total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) and triglyceride (TG) levels and demographic parameters of the two groups were compared. From a total of 70 participants, 64 completed the assigned treatment (31 in probiotics group and 33 in the control group).The two treatment groups were matched for age, sex, weight, height, BMI, waist and hip circumferences, and blood pressure. Results: Baseline evaluation revealed no difference between the probiotics group and control group levels of TC, HDL-C, LDL-C and TG. TC levels in the probiotics group decreased during treatment (237.2 vs. 212.7 mg/dL, p<0.05). TC and LDL-C levels in the control group increased significantly from their baseline levels during treatment. TC (212.7 vs 252.8 mg/dL, p<0.001), HDL-C (52.0 vs 59.1 mg/dL, p=0.04) and LDL-C (153.9 vs 182.1 mg/dL, p<0.01) levels in the probiotics group were significantly lower at the end of treatment than the corresponding levels in the control group. Conclusion: A combination of Lactobacillus acidophilus and Bifidobacterium bifidum decreased serum total cholesterol, LDL-cholesterol and HDL-cholesterol levels in hypercholesterolemic patients over a six week period. There was no effect on serum triglyceride or fasting blood glucose levels. © 2015, Journal of Clinical and Diagnostic Research. All Rights Reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationJournal of Clinical and Diagnostic Research. Vol 9, No.3 (2015)
dc.identifier.doi10.7860/JCDR/2015/11867.5728
dc.identifier.issn2249782X
dc.identifier.other2-s2.0-84924692200
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6162
dc.rights.holderScopus
dc.subject.otherCholesterol
dc.subject.otherHigh density lipoprotein cholesterol
dc.subject.otherLow density lipoprotein cholesterol
dc.subject.otherPlacebo
dc.subject.otherProbiotic agent
dc.subject.otherTriacylglycerol
dc.subject.otherAdult
dc.subject.otherArticle
dc.subject.otherBifidobacterium bifidum
dc.subject.otherCholesterol blood level
dc.subject.otherClinical article
dc.subject.otherControlled study
dc.subject.otherDouble blind procedure
dc.subject.otherFemale
dc.subject.otherHuman
dc.subject.otherHypercholesterolemia
dc.subject.otherLactobacillus acidophilus
dc.subject.otherLoose feces
dc.subject.otherMale
dc.subject.otherMiddle aged
dc.subject.otherNonhuman
dc.subject.otherObesity
dc.subject.otherRandomized controlled trial
dc.subject.otherSystolic blood pressure
dc.subject.otherBifidobacterium bifidum
dc.subject.otherLactobacillus acidophilus
dc.titleA randomized double-blind controlled trial of Lactobacillus acidophilus plus bifidobacterium bifidum versus placebo in patients with hypercholesterolemia
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84924692200&doi=10.7860%2fJCDR%2f2015%2f11867.5728&partnerID=40&md5=e4ab00df80066ba2c7f8f32d5bfd0266

Files